J. M. Shields

发表

The Gut-enriched Krüppel-like Factor (Krüppel-like Factor 4) Mediates the Transactivating Effect of p53 on the p21 WAF1/Cip1 Promoter*

Channing S. Mahatan, K. Kaestner, W. Zhang, 2000, The Journal of Biological Chemistry.

Identification and Characterization of a Gene Encoding a Gut-enriched Krüppel-like Factor Expressed during Growth Arrest*

J. M. Shields, V. Yang, R. Christy, 1996, The Journal of Biological Chemistry.

Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.

L. Carey, C. Livasy, A. Ivanova, 2012, The oncologist.

The Gut-enriched Krüppel-like Factor Suppresses the Activity of the CYP1A1 Promoter in an Sp1-dependent Fashion*

Y Fujii-Kuriyama, Y. Fujii‐Kuriyama, W. Zhang, 1998, The Journal of Biological Chemistry.

Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis.

S. Hamilton, J. M. Shields, V. Yang, 1998, Cancer research.

Expression of the gut‐enriched Krüppel‐like factor gene during development and intestinal tumorigenesis

K. Kaestner, J. M. Shields, V. Yang, 1997, FEBS letters.

Two Potent Nuclear Localization Signals in the Gut-enriched Krüppel-like Factor Define a Subfamily of Closely Related Krüppel Proteins*

J. M. Shields, V. Yang, 1997, The Journal of Biological Chemistry.

Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.

C. Livasy, J. M. Shields, R. Kimple, 2010, International journal of radiation oncology, biology, physics.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, A. Tan, 2013, The Journal of clinical investigation.

Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells

C. Der, C. Slingluff, J. M. Shields, 2004, Journal of Biological Chemistry.

Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer.

L. Carey, C. Livasy, A. Ivanova, 2010, The oncologist.

S. Smith‐Roe, J. M. Shields, W. Kaufmann, 2010, Cancer research.

Understanding Ras: 'it ain't over 'til it's over'.

C. Der, J. M. Shields, K. Pruitt, 2000, Trends in cell biology.

Identification of Ras-regulated genes by representational difference analysis.

S. Powers, C. Der, J. M. Shields, 2001, Methods in enzymology.

Radiosensitization of EGFR/HER2 positive pancreatic cancer is mediated by inhibition of Akt independent of Ras mutational status

J. Tepper, B. Calvo, J. M. Shields, 2010 .

CD200 is induced by ERK and is a potential therapeutic target in melanoma.

N. Sharpless, J. Serody, William Y. Kim, 2007, The Journal of clinical investigation.

Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma

Derek Y. Chiang, J. Parker, N. Sharpless, 2014, Pigment cell & melanoma research.

Opposing Roles of the Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Cascades in Ras-Mediated Downregulation of Tropomyosin

C. Der, J. M. Shields, K. Pruitt, 2002, Molecular and Cellular Biology.

Loss of Transgelin in Breast and Colon Tumors and in RIE-1 Cells by Ras Deregulation of Gene Expression through Raf-independent Pathways*

C. Der, J. M. Shields, K. Rogers-Graham, 2002, The Journal of Biological Chemistry.

Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth

C. Der, J. M. Shields, V. Khazak, 2007, Molecular Cancer Therapeutics.

Use of retrovirus expression of interfering RNA to determine the contribution of activated K-Ras and ras effector expression to human tumor cell growth.

C. Der, A. Baines, J. M. Shields, 2006, Methods in enzymology.

Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.

N. Sharpless, D. Rimm, C. Der, 2007, Cancer research.

Vascular channels formed by subpopulations of PECAM1+ melanoma cells

P. Dayton, J. M. Shields, R. Brekken, 2014, Nature Communications.

RKIP downregulates B-Raf kinase activity in melanoma cancer cells

J. M. Shields, K. Yeung, S. Beach, 2005, Oncogene.

Ras-mediated Loss of the Pro-apoptotic Response Protein Par-4 Is Mediated by DNA Hypermethylation through Raf-independent and Raf-dependent Signaling Cascades in Epithelial Cells*

C. Der, V. Rangnekar, J. M. Shields, 2005, Journal of Biological Chemistry.

Type of Melanoma Mitogen-Activated Protein Kinase Signaling Shows a New Lack of Extracellular Signal-Regulated Kinase

N. Sharpless, D. Rimm, C. Der, 2007 .

Mechanisms of chromosomal instability in melanoma

B. Omolo, J. M. Shields, W. Kaufmann, 2014, Environmental and molecular mutagenesis.

Development of DNA Damage Response Signaling Biomarkers using Automated, Quantitative Image Analysis

J. Ibrahim, C. Miller, B. Omolo, 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

A prognostic signature of defective p53‐dependent G1 checkpoint function in melanoma cell lines

H. Chu, C. Fan, J. Ibrahim, 2012, Pigment cell & melanoma research.

Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.

J. Ibrahim, N. Sharpless, J. M. Shields, 2008, The Journal of investigative dermatology.

Identification of the DNA sequence that interacts with the gut-enriched Krüppel-like factor.

J. M. Shields, V. Yang, J M Shields, 1998, Nucleic acids research.

Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.

J. M. Shields, R. Kimple, C. Sartor, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

J. M. Shields, W. Kaufmann, R. Kimple, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Radiosensitization of Epidermal Growth Factor Receptor/HER2–Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

J. Tepper, B. Calvo, J. M. Shields, 2010, Clinical Cancer Research.

Size-dependent increase in the levels of prota-glandin metabolites in adenomas of patients with familial adenomatous polyposis (FAP)

J. M. Shields, V. Yang, W. Hubbard, 1998 .

Colonic epithelium-enriched protein A4 is a proteolipid that exhibits ion channel characteristics.

J. M. Shields, V. Yang, C. Machamer, 1997, The American journal of physiology.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

C. Miller, S. Frye, J. M. Shields, 2013, The Journal of clinical investigation.

High-resolution immunogold localization of Giardia cyst wall antigens using field emission SEM with secondary and backscatter electron imaging.

J. Pawley, J. M. Shields, S. Erlandsen, 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.